1. At a Glance
Jubilant Ingrevia (CMP ₹808) is India’s specialty chemicals and life-sciences spin-off from Jubilant Life Sciences. Over FY21–25, revenue grew at a 1 % CAGR, profit at 34 % CAGR TTM, ROCE 11 %, ROE 9 %, and it trades at 51× EPS ₹15.8. A steady grower with niche muscle, but not exactly lighting fireworks.
2. Introduction with Hook
Remember when your chemistry teacher warned you about volatile reactions? Jubilant Ingrevia decided to bottle some of that volatility—minus the bangs—into pyridine, vitamin B3, and custom pharma intermediates. Half a decade in, the stock is more Bunsen burner than life-changing rocket. Let’s see if its mix of legacy and lab-grade specialty has any pop left.
3. Business Model (WTF Do They Even Do?)
- Core Products: Pyridine and derivatives (solvents, agrochemical building blocks).
- Nutrition & Pharma: Beta-Vitamin B3 (niacinamide) and B6, custom research & manufacturing for top global pharma.
- Agro Solutions: Intermediates for herbicides and pesticides, serving 7 of the world’s top 10 agrochemical majors.
- Integrated Model: From R&D to cGMP facilities—control over quality and cost.
- Global Reach: Exports to 70+ countries, lean manufacturing footprint in India keeps costs low.
4. Financials Overview – Profit, Margins, ROE, Growth
- Revenue: ₹4,178 Cr in FY25 vs ₹4,136 Cr in FY24 (+1 % TTM).
- EBITDA: OPM improved to 12 % in FY25 vs
